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When hemagglutinin (HA) and neuraminidase (NA) are presented together on an intact influenza virus particle, the antigens
are competitive, with HA dominant over NA in T- and B-cell priming. Immunization with mixtures of purified HA and NA
eliminates antigenic competition between HA and NA, as well as between N1-N2 NA mixtures. Evidence that vaccine
preparations contain influenza virus matrix (M1) and nucleoprotein (NP) prompted the investigation of possible competing
effects of these proteins on the anti-HA and anti-NA immune response. However, in BALB/c mice immunized with mixtures
of purified NA, M1, and NP no antigenic competition was demonstrated in either the primary or the secondary response.
When mice were immunized with intact virus or by infection, a lesser antibody response to M1 and NP was observed.
Furthermore, as measured by mean pulmonary virus titers after infection, no additional protective effects were conferred
on mice immunized with M1 and NP either alone or in conjunction with other antigens. These studies of influenza virus
antigen mixtures have implications for vaccination against influenza and other vaccines consisting of combinations of
antigens. q 1996 Academic Press, Inc.
Influenza virus neuraminidase (NA), whether admin- arations. There are no reported studies examining the
effect on the immune response of M1 and NP containedistered as a purified protein without adjuvant (Hocart
et al., 1995; Johansson et al., 1989; Johansson and in these vaccines. The interaction between the immune
system and the influenza viral proteins can be manifestedKilbourne, 1994) or administered in viral antigenic hy-
brids containing a hemagglutinin (HA) novel to human as intravirionic antigenic competition (Johansson et al.,
1987a, b, c) with consequent reduced response to oneexperience (e.g., H7N2) (Couch et al., 1974; Beutner
et al., 1979; Kilbourne, 1976), has been shown to be or more antigens, or as cognate help, where T-cells spe-
cific for internal protein antigens can support an HA- orimmunogenic and to engender protective immunity
both in a murine model (Johansson and Kilbourne, NA-specific B-cell response (Russell and Liew, 1979,
1980; Scherle and Gerhard, 1986). The present paper1994) and in humans (Couch et al., 1974; Beutner et
al., 1979; Johansson and Kilbourne, 1991; Johansson reports a comparison of the effects of dissociated M1
and NP or whole virus vaccine on the immune responseet al., 1993; Kilbourne et al., 1995). Immunization of
mice with purified NA of either N1 or N2 subtypes to NA and HA. The study demonstrates an absence of
anti-NA antigenic competition and a lack of antigenicinduces a specific immune response to NA which, al-
though infection-permissive across a broad range of competition against M1 and NP presented in dissociated
form. This is in contrast to the response to the wholeNA-antibody levels (Johansson et al., 1989; Johansson
and Kilbourne, 1994), results in the reduction of pulmo- virus vaccine where a relative decrease in M1- and NP-
specific antibody was accompanied by a greater T-cellnary virus titers below a pathogenic threshold (Johans-
son et al., 1989; Johansson and Kilbourne, 1991) and proliferative response. Furthermore, there were no bene-
fits observed from immunization with M1 and NP alonelessens the severity of infection as measured by reduc-
tion of weight loss (Johansson et al., 1993). as measured by mean pulmonary virus titers and weight
loss after live virus challenge.Recent studies have shown that purified NA-vaccine
(Hocart et al., 1995; Kilbourne et al., 1995), purified HA
preparations and conventional commercial whole virus
METHODSvaccine contain significant amounts of matrix (M1) and
nucleoprotein (NP) as measured by Western blotting and Animals
assay of polyclonal sera made against ‘‘purified’’ HA prep-
Inbred BALB/c female mice (Charles River Breeding
Laboratories), age 8 weeks at the beginning of the study,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (914) 993-4176. were used.
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Viruses
Purified influenza virus proteins NA, M1, and NP were
extracted from the H6N2 reassortant virus, A/Turkey/
Mass/75-Leningrad/360/86 (R), as previously described
(Johansson et al., 1989; Johansson and Kilbourne, 1994).
All the genes coding for the internal and nonstructural
proteins of reassortants used in this study were derived
from A/PR/8/34 (Johansson et al., 1989; Johansson and
Kilbourne, 1994). All viruses were grown in the allantoic
sac of 10-day-old chick embryos and stored in multiple
aliqouts at 0707. Mouse-adapted influenza reassortant
strains A/Leningrad/360/86 (R) H3N2 (X-91) and A/Aichi/
2/68 (R) (X-31b) were used to infect mice. They underwent
two sequential mouse lung passages at limiting dilution
followed by a single egg passage as described (Johans-
son et al., 1989; Johansson and Kilbourne, 1994). The
HAs of these viruses have an antigenic relatedness of
1%; the NAs of these viruses were antigenically related
by 25% as determined by the method of Archetti and
Horsfall (1950) as previously described (Johansson and
FIG. 1. Analysis of influenza virus proteins with silver stain of 10%Kilbourne, 1991). Ultraviolet (UV) irradiated whole X-91 SDS–polyacrylamide gel under nonreducing conditions: Lane A, A/PR/
virus was used as the whole virus vaccine. 8/34 influenza virus, demonstrating the relative molecular weight of
Purified NA used in this experiment was extracted from influenza virus proteins; NP, 56 kDa; M1, 27 kDa; N1-NA, 220 kDa.
Lane B; purified M1 and NP from A/PR/8/34 virus; Lane C: N2-NAoctylglucoside-disrupted H6N2Leningrad virus passed
purified from A/Leningrad/360/86 virus.through a DEAE–Sephadex A-50 column (Pharmacia-
LKB) as described (Johansson et al., 1989; Johansson
and Kilbourne, 1994). NA was characterized as a single
tion (data not shown). T-cell stimulation procedures wereband on SDS–polyacrylamide gels under nonreducing
as described previously (Johansson et al., 1987b, c). Anti-conditions (Fig. 1) and sera from mice immunized with
gen presenting cells (APC) were purified from spleensthis preparation failed to react with any other influenza
of freshly killed mice and were purified as the adherentviral proteins in ELISA (data not shown). Purified M1 and
fraction as described (Johansson et al., 1987c). APCsNP were obtained by Triton X-114 extraction from the
were incubated with 100 hemagglutinating units of A/PR/pellet of a 16,000 g for 20 min centrifugation of octylgluco-
8/34 H1N1 virus for 8 hr and then g-irradiated (2000 rad).side-disrupted virus (Johansson and Kilbourne, 1994; Jo-
Virus stimulated APCs (2 1 105/well) and T cells (4 1hansson et al., 1995). They were characterized as the
105/well) were co-cultured in a total volume of 200 ml ofonly influenza proteins on SDS–PAGE (Fig. 1).
DMEM with 5 mM 2-mercaptoethanol and 10% fetal calf
serum. Cultures were maintained at 377 in 5% CO2/95%Serologic methods
air for 36 hr and then pulsed with 1 mCi of [3H]thymidine
Neuraminidase inhibition assays (NI) and hemaggluti- per well. After 18 hr of incubation with label, cells were
nin inhibition tests (HI) were done as described pre- harvested and radioactivity was measured.
viously (Johansson et al., 1987a; Kilbourne et al., 1987)
with appropriate antigenically hybrid reassortant viruses:
Measurement of virusH1PR8N2 in NI and H3N1PR8 in HI. ELISAs were performed
as described (Johansson et al., 1989) using A/PR/8/34
Mouse pulmonary virus titers were measured as pre-H1N1 virus. Sera were obtained by retro-orbital bleeding
viously described (Schulman and Kilbourne, 1963).on the specified days and then stored at 0207.
Purified T-cell populations were obtained 7 days after
final boosting from the spleens of freshly killed animals Intranasal inoculation of mice
as described (Johansson et al., 1987b, c). Briefly, splenic
cell suspensions were enriched for T-cells by passage One hundred mouse infectious dose-50 (MID50) of
mouse adapted X-91 virus for the first infection, X-31bover a nylon wool column and further depleted of B-cells
by panning to remove Ig/ cells. Cytofluorometric analysis virus for the second infection, or phosphate-buffered sa-
line (PBS) for the mock infected group was administeredshowed that fluorescein-labeled anti-Thy 1.2 monoclonal
antibody stained 95% of the cells in the final prepara- in a total volume of 0.03 ml to lightly anesthesitized mice.
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FIG. 2. Serologic response to immunization measured by (A) neuraminidase inhibition antibody, numbers are log 2 mean dilution endpoints of
triplicate wells. (B) hemagglutination inhibition antibody, numbers are log 2 mean dilution endpoints of triplicate wells. (C) T-cell proliferation
measured by [3H]thymidine uptake; numbers are means of triplicate cultures 1 1003. (D) ELISA antibody to M1 and NP. Numbers represent the
mean of endpoint titers from triplicate wells. The endpoint was taken as the highest dilution of antibody producing an absorbance value threefold
above background (absorbance value from an antibody free well). For all panels, mice were immunized as follows: Group A; NA and M1/NP, Group
B; M1/NP, Group C; NA, Group D; H3N2 whole virus, Group E; PBS.
Immunization and infection schedules after the first infection to measure the response to infec-
tion (Fig. 3). Seven days after each infection five mice
One hundred eighty mice were randomly divided into from each group were randomly chosen for assays of
groups of 30. Mice were injected intraperitoneally with mean pulmonary virus titers.
5 mg of purified NA (group C), 10 mg of an equimolar
mixture of M1 and NP (group B), a mixture of 5 mg of NA Statistical methods
and 10 mg of the M/NP solution (group A), whole UV-
Data were analyzed by multivariate analysis of vari-inactivated virus (WV) adjusted to equivalent NA activity
ance (ANOVA) and Tukey test subsequent to ANOVAof the 5-mg group (group D), or PBS (groups E and F).
using the SAS statistical package (Cary, NC).Mice were given a second injection of 1 mg of their re-
spective vaccines 21 days after primary immunization.
RESULTSMice received their primary immunization on Day 1, and
boosting occurred on Day 21. All mice were bled on Day Response to vaccination
28 to assay the response to immunization (Fig. 2). Two
days later on Day 30, mice were intranasally inoculated NA and HA antibody response. A single initial 5-mg
injection of N2-NA was previously shown to be thewith their first viral challenge. The second viral challenge
was given on Day 80. Mice were bled on 7-day intervals minimal priming immunogenic dose in immunologi-
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cally naive mice (Johansson et al., 1989; Johansson D (WV vaccine), which had evidence of infection in only
one of five test mice. Unimmunized mice had the signifi-and Kilbourne, 1994). In this study all mice initially
immunized and boosted with an NA containing vaccine cantly highest (P  0.01) mean pulmonary virus titers
(107.0) subsequent to infection, but were statistically indis-had an anti-NA response consistent with a secondary
immune response (Fig. 2A). There were no statistically tinguishable from animals initially immunized with M/NP
(Group B, mean pulmonary virus titers was 106.5). Thesignificant differences in NA antibody level between
Group A (NA / M/NP) and Group C (NA alone) mice, lowest mean pulmonary virus titer (101.3) was from mice
vaccinated with WV (Group D), whereas mice immunizedsuggesting that neither additional help nor antigenic
competition occurred among the antigens in these mix- with NA-containing vaccines (Groups A and C) had inter-
mediate mean pulmonary virus titers that were signifi-tures. Mice immunized with WV vaccine (Group D)
were the only animals that had HA antibodies after cantly different from unimmunized mice, WV vaccinated
mice, and M/NP immunized animals.immunization (Fig. 2B); the NA antibody response was
significantly (P  0.02) less than in mice immunized Mice immunized with NA (Group C), NA and M1/
NP (Group A), or WV (Group D) did not experience awith NA without HA (i.e., Fig. 2A, Groups A and C).
This muted response to NA in the presence of HA significant weight loss or lack of developmental weight
gain relative to uninfected control animals (Fig. 3F).represents the effect of HA-NA antigenic competition
(Johansson et al., 1987a; Kilbourne et al., 1987). However, unimmunized and M1/NP vaccinated mice
experienced a significant (P  0.02) weight loss andResponse to M1 and NP. A significant M1 protein and
NP antibody response measured by ELISA occurred in deviation of normal development weight gain. It is in-
teresting to note that the addition of M1/NP to the NAall mice immunized with vaccines containing M1 and NP
(i.e., Groups A, B, and D) (Fig. 2D). Although WV vacci- vaccine (Group A) did not confer additional immunity
on recipients as measured by mean pulmonary virusnated mice (Group D) produced half the antibody com-
pared to mice vaccinated with dissociated M1/NP prepa- titers and weight loss.
NA and HA antibody response. Infection induced a riserations (Groups A and B), there were no statistically sig-
nificant differences in M1 and NP antibody measured by in NI antibody (Fig. 3A) in all groups. Groups A and C,
initially immunized with vaccines that contain purifiedELISA among these mice. However, there were statisti-
cally significant differences (P  0.04) among groups in NA, had the highest anti-N2 response. Groups B (M1/NP
vaccine), Group D (WV vaccine), and Group E (unimmu-[3H]thymidine uptake when purified T-cells were stimu-
lated with whole intact H1N1PR8 virus (Fig. 2C). Animals nized mice) had the least amounts of NI antibody. Fur-
thermore, the large amount of NI antibody produced ininitially immunized with WV vaccine (Group D) had the
highest stimulation, whereas Groups A and B (M1/NP Groups A and C and the small amount of NI antibody in
Group B produced subsequent to infection suggest thatcontaining vaccines) were statistically indistinguishable.
NA vaccinated (Group C) mice had only a background vaccination with purified M1/NP had neither a competi-
tive nor a cooperative effect on NA immunization.level of stimulation.
Animals initially immunized with WV vaccine (Group
D) had the highest HI antibody made in response toResponse to infection
infection (Fig. 3B). Groups A and B (M1/NP containing
vaccines) were statistically indistinguishable from eachMean pulmonary virus titers and weight loss. In pre-
viously unimmunized mice (Group E) infection with other in HI antibody response; these groups saw HA for
the first time during infection with H3N2 virus. Immuniza-mouse-adapted A/Leningrad/360/86 (R) H3N2 virus in-
duced antibodies to H3, N2, and M1/NP as measured in tion with purified M1/NP had no enhancing effect or neg-
ative effect on the response to HA.NI, HI, and ELISA, respectively (Figs. 3A, 3B, and 3D).
The antibody levels seen in these mice were similar to Response to M1 and NP. Statistical analysis of T-cell
proliferation (Fig. 3C) in response to H1N1 after infectionthose seen in previous studies (Johansson et al., 1989;
Johansson and Kilbourne, 1991). This virus killed 30–40% revealed no significant differences in [3H]thymidine up-
take among groups A (NA and M1/NP), B (M1/NP), andof M1/NP immunized and unimmunized infected mice,
respectively. One hundred percent of randomly chosen D (WV), although Group D had arithmetically the highest
response, approximately twice the level of proliferationtest mice had evidence of infection with influenza virus
with a mean PVT of 107.0 PFU/ml of undiluted lung prepa- of the other groups. Groups C (NA vaccine) and E (unim-
munized) were not significantly different from each other.rations (Fig. 3E, Group E). These mice also suffered the
greatest weight loss after infection (Fig. 3F). Infection was the initial exposure to M1 and NP antigens
for these animals. Therefore the proliferative response inIntranasal inoculation of mouse-adapted virus into pre-
viously immunized mice had varying effects modified by Groups C and E represents a primary immune response.
Infection induced an antibody response to M1 and NPthe type of vaccine animals received. There was an 100%
infection rate in all vaccine groups (Fig. 3E), except Group as measured by ELISA in all groups (Fig. 3D). Groups A
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FIG. 3. Response after infection measured by: (A) neuraminidase inhibition antibody, numbers are log 2 mean dilution endpoints of triplicate
wells. (B) Hemagglutination inhibition antibody, numbers are log 2 mean dilution endpoints of triplicate wells. (C) T-cell proliferation measured by
[3H]thymidine uptake; numbers are means of triplicate cultures 1 1003. (D) ELISA antibody to M1 and NP. Numbers represent the mean of endpoint
titers from triplicate wells. The endpoint was taken as the highest dilution of antibody producing an absorbance value threefold above background
(absorbance value from an antibody free well). (E) Pulmonary virus titers; numbers are log 10 mean dilution endpoints of lung preparations in eggs;
in group D with a single infected mouse the mean value of all animals was calculated using a value of 1.0 for uninfected mice. (F) Weight loss as
measured in grams. Numbers represent the mean of individually weighted mice. For all panels, mice were immunized as follows: Group A, NA and
M1/NP (j); Group B, M1/NP (m); Group C, NA (/); Group D, H3N2 whole virus (l); Group E, PBS(1); Group F, uninfected control (l).
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FIG. 4. Response to the second (heterovariant virus) infection measured by pulmonary virus titers. Numbers are log 10 mean dilution endpoints
of lung preparations in eggs. Mice were immunized as follows: Group A, NA and M1/NP; Group B, M1/NP; Group C, NA; Group D, H3N2 whole
virus; Group E, PBS; Group F, mice initially injected with PBS and mock infected during the first infection.
and B, both initially immunized with a preparation con- DISCUSSION
taining M1 and NP, had the significantly highest anti-M1/
Combining several antigens into a single vaccine prepa-NP response, in what is apparently a secondary immune
ration is not novel or unique to influenza vaccines and isresponse. Groups C, D, and E had a very low M1/NP
often driven by administrative and financial considerations.antibody response to infection. There were no significant
However, presenting multiple antigens in a given vaccinedifferences among Groups C, D, and E in ELISA antibody
with the goal of attaining immunization and subsequentto M1/NP. It is interesting, however, to note that mice
protection equivalent to that seen with the individual com-initially immunized with WV vaccine (Group D) had the
ponents can be problematic. Barr and Llewellyn-Joneshighest primary T-cell proliferative response to H1N1 vi-
(1953a, b, 1955) observed ‘‘immunologic interference’’rus (Fig. 2C) but the lowest antibody response to M and
among components of the diphtheria–pertussis–tetanusNP among groups immunized with vaccines containing
(DPT) vaccine in humans. More recently, Jalil et al. (1991)M/NP (Fig. 2D). Furthermore, after infection WV immu-
found evidence of reduced serologic response to a rhesusnized mice had the greatest T-cell proliferative response
rotavirus vaccine when it was administered concomitantlyto H1N1 virus (Fig. 3D) but these same mice had a sec-
with DPT and inactivated or oral polio vaccine. Taussigondary M/NP antibody response indistinguishable from
(1974) described this form of antigenic competition (i.e., amice immunized with purified NA (Group C) or PBS
relative decrease in immune response to an antigen when(Group E). These differences in immune response most
presented within a mixture) as intermolecular antigeniclikely reflect differences in antigen processing of purified
competition. The solution to avoid competition when mixedantigens and whole virus.
antigens were injected was to adjust the relative ratios of
antigens to ‘‘balance’’ the immune response.Response to a nonhomologous second infection
In contrast, intravirionic antigenic competition (Johans-
son et al., 1987a) is dependent not only on the concomi-Intranasal inoculation of mouse-adapted heterovariant
A/Aichi/2/68 (R) H3N2 virus into previously uninfected tant administration of antigens but upon the fact that
these antigens are physically linked (i.e., as antigens onand unimmunized mice (Fig. 4, Group F) resulted in a
mean pulmonary virus titers of 107.5 PFU/ml of undiluted the same viral particle) and therefore are taken up and
processed together (Johansson et al., 1987a, b, c). Previ-lung preparation. One hundred percent of randomly cho-
sen test mice were infected. But as with the first infection, ous studies from our laboratory of NA specific antigenic-
hybrid vaccine have shown that the relatively diminishedthe impact of infection was modified as a function of
previous immunization. Mice initially immunized with vac- antibody response to NA occurs only when both NA and
HA are presented on the same viral particle despite evi-cine containing purified NA (Groups A and C) had no
evidence of infection, whereas animals initially immu- dence that the purified glycoproteins are equivalent anti-
gens on a weight-for-weight basis (Johansson et al.,nized with dissociated M1/NP (Group B) or WV vaccine
(Group D) had mean pulmonary virus titers that were 1989; Johansson and Kilbourne, 1994). HA immunogenic-
ity is dominant over NA in both B- and T-cell priming asnot significantly different from each other or from those
animals that received PBS initially (Group E) (mean pul- a result of intravirionic antigenic competition (Johansson
et al., 1987a, b, c). Further studies found no indication ofmonary virus titers were 104.1, 103.8, and 104.3, respec-
tively). intramolecular or intravirionic antigenic competition of
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mixed but physically dissociated N1 and N2 NAs (Johans- and then receive help from M1 and NP specific T-cells,
resulting in an increase in both antibody and T-cell stimu-son and Kilbourne, 1994). However, antigenic competi-
tion was again noted between NA and HA, albeit in the lation to M1 and NP. Indeed, these findings suggest that
cognate help and intravirionic antigenic competition mayreverse direction (i.e., HA antibody was reduced) when
parenteral priming with NA preceded whole virus chal- be manifestations of the same immunologic event.
During the past decade much effort has been madelenge infection (Johansson and Kilbourne, 1994).
None of these studies addressed the potential for anti- to explore the immune response to the internal proteins
of influenza A virus, especially M1 and NP. Both of thesegenic competition or an increase in the immune response
among dissociated internal proteins, such as M1 and NP proteins are highly conserved (Claas et al., 1994; Huddel-
ston and Brownlee; 1982, Kida et al., 1994; Mandler andand the surface glycoproteins. The present experiments
have assumed importance since it was discovered during Scholtissek, 1989) and induce a cross-reactive cytotoxic
T lymphocyte (CTL) response (Fleischer et al., 1985;preparation of NA-specific vaccine for human trials that
‘‘purified’’ NA preparations contained contaminating M1 and McMichael et al., 1986; Reiss and Schulman, 1980; Yew-
dell et al., 1985). CD8/ CTL kill virally infected cells whenNP, albeit in proportions markedly less than that found in
whole virus vaccine preparations (Hocart et al., 1995). Also, their T-cell receptors recognize viral peptides associated
with Class I MHC molecules on the surface of infectedreagent antisera produced to purified HA for evaluating
viral HA in potential vaccine lots reacted not only with HA cells. Yewdell et al. (1985) claim that a ‘‘significant’’ num-
ber of cross-reactive CTLs in BALB/c mice recognizebut M1 and NP in Western blotting (Hocart et al., 1995).
Work from other laboratories had demonstrated that T-cell NP. Using limiting dilution to determine CTL precursor
frequency, Andrew et al. (1986) found that approximatelyclones specific for M and NP can support an HA antibody
response (Russell and Liew, 1979, 1980; Scherle and Ger- 30% of the CTLs recognized NP. CTLs generated in the
course of viral infection of mice recognize M1 (Fleischerhard, 1986), leading us to question the effect that this ‘‘con-
taminating’’ M1 and NP might have on the subsequent im- et al., 1985; Braciale, 1977; Braciale and Yap, 1978). Many
studies using a variety of immunization schemes, includ-mune response to NA.
The present report confirms earlier findings that: (i) ing purified proteins (Webster and Askonas; 1980), iso-
lated peptides (Townsend et al, 1984), vaccinia recombi-purified NA is highly immunogenic without adjuvant; (ii)
anti-NA antigenic competition did not occur after infec- nants expressing influenza viral proteins (Andrew et al.,
1987), and injection of DNA encoding viral protein (Ulmertion in NA-immunized mice, (iii) neither antigenic compe-
tition nor immune enhancement occurred in mice immu- et al., 1993) have shown an induction of immune re-
sponse to heterotypic influenza A viruses. However, othernized with dissociated NA and M1/NP. However, a rela-
tive diminution of the M1/NP antibody response is studies have failed to demonstrate protection from infec-
tion despite the presence of M1 and NP specific CTLsevident in animals immunized with whole intact virus
vaccine preceding viral infection, yet these animals had (Lawson et al., 1994, Yap and Ida, 1977). Indeed, despite
evidence that live and inactivated influenza vaccines in-the greatest T-cell response to M1 and NP. This effect
is eliminated when proteins are injected together as dis- duce cross-reactive T-cells in humans (McMicheal et al.,
1981, McMicheal et al., 1983) and mice (Ennis et al., 1981;associated antigens. The phenomenon can be explained
as a result of cognate help (Scherle and Gerhard, 1986), Wraith, 1986), reinfection with homologous or heterotypic
virus occurs.that is, B-cells specific for the influenza virus surface
antigens, HA and NA, are able to scavenge whole or Despite inducing a T-cell proliferative response and a
humoral response to M1 and NP, vaccination with disas-partially disrupted virus particles, then process and pres-
ent both surface and internal antigens, and are thereby sociated M1/NP did not protect mice from the effects of
homologous infection as measured by mean pulmonaryable to receive help and stimulation from M1 and NP
specific T-cells. B-cells specific for the internal proteins virus titers (Fig. 3E) or weight loss (Fig. 3F). Further, after
a second infection with a viral reassortant containingwould have little chance to be exposed to these antigens
at the time of infection. The result of these interactions heterotypic HA and NA (A/Aichi/2/68) but homotypic (A/
PR/8/34) M1 and NP there were no differences in meanis manifested as an increase in anti-NA and HA antibody
with a concurrent low anti-M1 and NP antibody response, pulmonary virus titers among animals initially immunized
with M1/NP, WV, or PBS (Fig. 4). These animals did haveyet one sees an increase in T-cell proliferation to the
internal antigens. T-cells specific for M1 and NP could a reduction in mean pulmonary virus titers relative to
unimmunized, previously uninfected control animals,be stimulated by the presentation of M1 and NP epitopes
in conjunction with MHC Class II antigen on the surface most probably mediated via immune recognition of
cross-reactive epitopes on internal proteins and NA, con-of the HA or NA specific B cells, after these B cells
have taken up and processed these antigens. In contrast, sidering that the HAs used for infection had less than
1% antigenic relatedness (Johansson and Kilbourne,disassociated M1/NP can only be recognized, pro-
cessed, and presented by M1 and NP specific B-cells 1991). By whatever mechanism, animals initially immu-
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Huddelston, J., and Brownlee, G. (1982). The sequence of the nucleopro-nized with vaccines containing NA only 25% antigenically
tein gene of human influenza A virus strain A/NT/60/68. Nucleic Acidsrelated to the final challenge virus (Johansson and Kil-
Res. 10, 1029–1038.
bourne, 1991) had complete protection against hetero- Jalil, F., Zuman, S., Carlsson, B., Glass, R. I., Kapikian, A. Z., Mellander,
typic infection. This was most likely mediated via shared L., and Hanson, L. A. (1991). Immunogenicity and reactogenicity of
cross-reactive epitopes on internal proteins and on the rhesus rotavirus vaccine given in combination with oral or inactivated
poliovirus vaccines and diphtheria–tetanus–pertussis vaccine.NAs. Apparently, definitive immunity was engendered
Trans. R. Soc. Trop. Med. Hyg. 85, 292–296.when the first infection was modified by the presence of
Johansson, B. E., Bucher, D. J., and Kilbourne, E. D. (1989). Purified influ-anti-NA immunity. Early work with purified HA and NA
enza virus hemagglutinin and neuraminidase are equivalent immuno-
demonstrated that an immune response to the surface gens. J. Virol. 63, 1239–1246.
glycoproteins affords the same protection as whole virus Johansson, B. E., Gradjower, B., and Kilbourne, E. D. (1993). Infection
permissive immunization with influenza virus neuraminidase pre-immunization (Johansson et al., 1989, Johansson and Kil-
vents weight loss of infected mice. Vaccine 10, 1037–1039.bourne, 1994). We conclude that effective influenza vac-
Johansson, B. E., and Kilbourne, E. D. (1991). Comparative long termcines need not contain internal viral antigens although
effects in a mouse model system of influenza whole virus vaccine and
we have demonstrated the capacity of these antigens to purified neuraminidase vaccine followed by sequential infections. J.
prime M1/NP specific B-cell and T-cell populations. Infect. Dis. 162, 800–809.
Johansson, B. E., and Kilbourne, E. D. (1994). Immunization with purified
N1 and N2 influenza virus neuraminidase demonstrates cross-reac-REFERENCES
tivity without antigenic competition. Proc. Natl. Acad. Sci. USA 91,
Andrew, M. E., Coupar, B. E., Ada, G. L., and Boyle, D. B. (1986). Cell- 2358–2361.
mediated immune responses to influenza virus antigens expressed Johansson, B. E., Moran, T. M., Bona, C. A., Popple, S. W., and Kilbourne,
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